Valuation: PTC Therapeutics, Inc.

Market Cap 6.15B 5.34B 5B 4.56B 8.57B 586B 8.71B 58.94B 22.96B 294B 23.09B 22.59B 980B P/E 2026 *
41.8x
P/E 2027 * 26.1x
Enterprise Value 6.12B 5.31B 4.98B 4.54B 8.53B 584B 8.67B 58.66B 22.85B 292B 22.98B 22.48B 975B EV / Sales 2026 *
4.85x
EV / Sales 2027 * 2.94x
Free-Float
92.61%
Yield 2026 *
-
Yield 2027 * -
1 day-1.44%
1 week+5.12%
Current month+6.81%
1 month-14.39%
3 months-5.48%
6 months+2.43%
Current year-4.37%
1 week 68.99
Extreme 68.99
75
1 month 64.57
Extreme 64.5675
83.68
Current year 61.43
Extreme 61.43
90.87
1 year 45.42
Extreme 45.425
90.87
3 years 17.53
Extreme 17.53
90.87
5 years 17.53
Extreme 17.53
90.87
10 years 4.03
Extreme 4.03
90.87
Manager TitleAgeSince
Chief Executive Officer 54 2023-03-21
Director of Finance/CFO 41 2023-07-12
Chief Tech/Sci/R&D Officer - 2017-09-30
Director TitleAgeSince
Chairman 74 2004-10-31
Chairman 80 1998-03-30
Director/Board Member 65 2005-11-30
Date Insider Type Main position Quantity % Market Cap.
8/4/26 Sell

Chief Executive Officer

-10,292 0.0124%
7/28/26 Other

Director

200,401 0.2416%
7/28/26 Free

Director

11,213 0.0135%
Change 5-day change 1-year change 3-year change Capi.($)
-1.44%+5.12%+67.76%+74.28% 6.15B
+0.43%+9.38%+92.10%+130.99% 1,083B
+0.41%+2.33%+50.07%+50.05% 626B
-0.53%+2.03%+25.23%+63.46% 442B
-0.92%+2.18%+48.40%+37.85% 363B
-1.32%-0.32%+29.35%+36.81% 295B
-1.20%-0.32%+6.03%+6.09% 248B
+0.45%+6.71%+45.98%+58.54% 224B
-2.51%-2.63%-7.16%-51.74% 210B
+0.07%+0.46%+12.78%+69.84% 168B
Average -0.70%+3.26%+37.06%+47.62% 366.53B
Weighted average by Cap. -0.33%+4.29%+49.47%+65.98%

Financials

2026 *2027 *
Net sales 1.26B 1.1B 1.03B 936M 1.76B 120B 1.79B 12.11B 4.72B 60.31B 4.74B 4.64B 201B 1.36B 1.18B 1.11B 1.01B 1.9B 130B 1.93B 13.05B 5.08B 65.01B 5.11B 5B 217B
Net income 153M 133M 125M 114M 214M 14.61B 217M 1.47B 572M 7.32B 575M 563M 24.43B 214M 186M 174M 159M 299M 20.42B 303M 2.05B 800M 10.23B 804M 787M 34.13B
Net Debt -29.41M -25.51M -23.92M -21.79M -40.99M -2.8B -41.63M -282M -110M -1.4B -110M -108M -4.69B -2.15B -1.86B -1.75B -1.59B -2.99B -204B -3.04B -20.56B -8.01B -102B -8.05B -7.88B -342B
Logo PTC Therapeutics, Inc.
PTC Therapeutics, Inc. is a global biopharmaceutical company. The Company is focused on the discovery, development, and commercialization of clinically differentiated medicines that provide benefits to children and adults living with rare disorders. Its diversified therapeutic portfolio includes several commercial products and product candidates in various stages of development, including discovery, research and clinical stages, focused on the development of new treatments for multiple therapeutic areas for rare diseases relating to neurology and metabolism. It has two products, Translarna (ataluren) and Emflaza (deflazacort), for the treatment of Duchenne muscular dystrophy (DMD) a rare, life-threatening disorder. Its Upstaza, a gene therapy for the treatment of Aromatic L-Amino Decarboxylase (AADC) deficiency, a rare central nervous system (CNS) disorder. Its Tegsedi and Waylivra are for the treatment of rare diseases. Its Evrysdi, a treatment for spinal muscular atrophy (SMA).
Employees
991
Date Price Change Volume
26-08-12 US$72.64 -1.44% 973,032
26-08-11 US$73.70 -1.25% 763,594
26-08-10 US$74.63 +1.80% 826,179
26-08-07 US$73.31 +3.47% 963,179
26-08-06 US$70.85 +2.37% 928,898
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
B
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
14
Last Close Price
73.70USD
Average target price
97.86USD
Spread / Average Target
+32.78%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. PTCT Stock